Author

Vinay Jadhav

Observed name: V Jadhav

Observed institution: GlaxoSmithKline (India)

OpenAlex ID: A5072288543

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

2021 · Rakesh Popat, Ashraf Z. Badros, et al. · Blood · 4

Changes in renal function with belantamab mafodotin–containing regimens in patients with relapsed or refractory multiple myeloma and baseline mild or moderate renal impairment: post hoc results from DREAMM-7 and DREAMM-8

2026 · Marcelo Pitombeira de Lacerda, Meletios Dimopoulos, et al. · NCODA Oncology and Hematology Meeting Abstracts

EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model

2025 · Attaya Suvannasankha, Martin Kaiser, et al. · Value in Health

EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

2025 · Martin Kaiser, Attaya Suvannasankha, et al. · Value in Health

Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.

2025 · Marcelo Pitombeira de Lacerda, Meletios Athanasios Dimopoulos, et al. · Journal of Clinical Oncology

Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.

2025 · Meral Beksac, Alessandro Corso, et al. · Journal of Clinical Oncology

P13: Can Patient-reported Ocular Symptoms Guide Dose Modifications in Patients With Relapsed/refractory Multiple Myeloma Receiving Belantamab Mafodotin?

2022 · R Popat, A Badros, et al. · HemaSphere

Works count: 7

Citation count: 4

H-index: 1

I10-index: